Trial Profile

A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olanzapine (Primary) ; Olanzapine (Primary) ; Haloperidol decanoate; Haloperidol decanoate
Indications Schizophrenia
Focus Therapeutic Use
Acronyms HGMT
Sponsors Eli Lilly and Company

Most Recent Events

30 Jul 2022 This trial has been completed in France (End Date: 13 June 2008) according to European Clinical Trials Database record.
18 Aug 2011 This trial is recruiting in France and has discontinued in Hungary and United Kingdom.
18 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com